Manufacture > Plant Samyang Genex was the first company to commercialize the mass production of paclitaxel (Genexol®) through the plant cell culture technology. After several dedicated years of extensive research on the plant cell culture and purification technology, Samyang Genex decided to make a giant leap toward the production of highly pure paclitaxel in mass quantity, which can satisfy the world's demand. The decision became reality with Daejeon Genexol Plant, which was established in 1997. Daejeon Genexol Plant runs under the strict standards of GMP (Good Manufacturing Practice), constantly updating and upgrading to the current trends in GMP. The Plant has proven its GMP compliance through several inspections by governmental agencies from Korea, Hungary, and Germany. Our highly purified paclitaxel is being sold world-widely with the product name Genexol®. Address : 1688-3 Sinil-dong, Daedeok-gu, Daejeon 306-230, Korea Tel : +82-42-930-9300 Fax : +82-2-6234-9302 1993-1998 Research and Development Aug. 1996 Construction of the Plant initiated Aug. 1997 Completion of the Plant June 1998 Acquired Manufacturing License (Korea) Aug. 1998 Filed United States Drug Master File (USDMF#14338) Jan. 2002 Acquired Bulk GMP (Korea) Sep. 2004 Passed inspection from Hungary government Oct. 2004 Acquired GMP Certification (Hungary) Nov. 2004 Passed inspection from Hamburg government, Germany Dec. 2004 Acquired GMP Certification & Import License (Germany)